The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

Women who are conflicted while choosing between an injectable contraceptive, a copper intrauterine device (IUD) or a hormonal implant may not need to worry about its impact on human papillomavirus (HPV).

What Is Human Papillomavirus (HPV)?

HPV is one of the most common sexually transmitted infections worldwide. While many HPV infections go away on their own without causing problems, some high-risk types can persist and increase the risk of cervical cancer in the long run.

Before this study, scientists debated whether hormonal contraceptives could affect a woman's immune response, making it easier to contract HPV or harder for the body to clear the infection.

Birth Control Choice May Not Influence HPV Risk

According to a new study published in The Lancet Regional Health – Africa, your choice of contraception may not have an impact on the risk of contracting HPV.

Researchers found that women using a commonly used injectable contraceptive known as depot medroxyprogesterone acetate (DMPA-IM), copper IUDs, and levonorgestrel implants had similar chances of contracting HPV and clearing existing infections.

About The Lancet Study

Also read: You Can Still Get HPV If You're Not Sexually Active

The researchers examined data from women who participated in the large ECHO (Evidence for Contraceptive Options and HIV Outcomes) clinical trial. Participants were randomly assigned to one of three contraceptive methods:

• Depot medroxyprogesterone acetate (DMPA-IM) injectable contraceptive

• Copper IUD

• Levonorgestrel implant

They then compared how often women acquired HPV during the study and how often those who already had HPV were able to clear the infection naturally. The analysis found no meaningful differences between the three contraceptive methods.

Women using the injectable contraceptive were no more likely to acquire HPV than those using a copper IUD or a hormonal implant. Similarly, women across all three groups cleared HPV infections at comparable rates.

Significance Of The Study

Also read: Teplizumab: UK NHS To Roll Out World-First Drug To Delay Onset Of Type 1 Diabetes

Earlier studies finding the link between hormonal contraceptives and HPV have reported mixed results. Some suggested that hormonal birth control might increase the risk of HPV infection or make infections last longer, while others found no clear outcomes.

This new research provides stronger evidence because it is based on a randomized clinical trial. The findings suggest that the type of contraceptive a woman chooses is unlikely to have an impact on her risk of getting HPV or her body's ability to clear the infection.

Women Can Take Control Of Their Contraceptive Choice

The study allows women to choose between these commonly used contraceptive methods based on factors such as effectiveness, convenience, side effects, and personal preference, rather than concerns about HPV risk.

However, experts stress that no contraceptive method protects against sexually transmitted infections, including HPV. Using condoms can help reduce the risk of HPV and other STIs.

The human papillomavirus causes more than 200 known infections. While some types lead to benign skin warts, others are responsible for severe health threats, such as cervical, throat, anal, and penile cancers. The HPV vaccine provides strong protection against the most lethal strains, avoiding long-term health complications.

The HPV vaccine helps the immune system recognize and fight off high-risk strains of the virus before they cause harm. It protects against:

• Genital warts

• Cervical cancer

• Vaginal, vulvar, anal, and penile cancers

• Mouth, throat, head, and neck cancers linked to HPV

Experts also stress that HPV vaccination and regular cervical cancer screening remain the most effective ways to prevent cervical cancer and detect abnormal changes early.

People in the UK can, from today, access the Wegovy weight loss pill through pharmacies with a doctor's prescription. It is the first oral glucagon-like peptide-1 (GLP-1) medicine approved in the UK for weight loss.

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the tablet on June 11, marking the first oral GLP-1 treatment available in the country for obesity management.

"Having met the MHRA's rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management," Julian Beach, Executive Director of Healthcare Quality and Access at the MHRA, said in a statement.

"As with all GLP-1 receptor agonists, this is a prescription-only medication," Beach added.

Novo Nordisk called it an "important milestone for obesity care in the UK".

"For the first time, people living with obesity have access to a GLP-1 treatment in a daily pill, allowing them the choice and flexibility of oral treatment to support their long-term weight management," said Sebnem Avsar Tuna, General Manager at Novo Nordisk UK.

Wegovy Weight Loss Pill: Who Is Eligible?

Also read: US Medicare Set To Cover GLP-1 Drugs For Weight Loss: All You Should Know About Eligibility, Costs

The semaglutide (Wegovy) tablet can be prescribed alongside a reduced-calorie diet and increased physical activity for adults who:

• Have obesity (BMI of 30 or above), or
• Are overweight (BMI between 27 and 30) and have at least one weight-related comorbidity.

Wegovy Weight Loss Pill Dosage

Patients must begin with the lowest dose of 1.5 mg once daily, which can be gradually increased to:

• 4 mg
• 9 mg
• 25 mg

People currently taking 2.4 mg weekly semaglutide injections privately can switch directly to 25 mg semaglutide tablets once daily.

Wegovy: How To Take The Tablet

Read More: This 45-Minute Weight-Loss Procedure May Work Better Than Semaglutide Pills, Study Claims

According to the MHRA, the tablet should be:

• Taken whole on an empty stomach after fasting for at least eight hours.
• Swallowed with a small sip of water.
• Followed by no food or drink for at least 30 minutes, as eating or drinking sooner reduces the drug's absorption.

Patients are advised to carefully follow the instructions in the Patient Information Leaflet.

How Does Wegovy Work?

Semaglutide is a GLP-1 receptor agonist that mimics the action of the naturally occurring GLP-1 hormone released after eating.

It acts on areas of the brain that regulate appetite by:

• Helping people feel fuller for longer.
• Reducing hunger.
• Decreasing food cravings.

Wegovy: Is It Available On The NHS?

Not yet. Although the medicine has received MHRA approval, it is not currently available through the NHS.

The MHRA said NHS availability will depend on the usual evaluation process by the National Institute for Health and Care Excellence (NICE).

NICE said Novo Nordisk has not yet formally approached it, but that it is in active discussions with the company, BBC reported.

Wegovy Weight Loss Pill: What Are The Side Effects?

The most commonly reported side effects are gastrointestinal and include:

• Nausea
• Diarrhea
• Constipation
• Vomiting

The MHRA said it will continue to monitor the medicine's safety and effectiveness. Anyone experiencing side effects should speak to their doctor, pharmacist, or nurse and report them through the MHRA Yellow Card scheme.

Pharmacies Expect High Demand

Community pharmacies say they are preparing for a surge in demand following the launch. The National Pharmacy Association (NPA) urged patients to obtain the medicine only from regulated pharmacies following a proper clinical consultation.

The Democratic Republic of the Congo (DRC) is battling one of its deadliest Ebola outbreaks in recent years. While it is driving innovation in medical science with new clinical trials and diagnostic tests, it is also a stark reminder of the urgency to contain the outbreak as soon as possible.

What Makes This Ebola Outbreak Deadlier?

According to the latest data, the death toll in DRC has now crossed 500 with at least 1,528 cases that are reported and confirmed.

While Ebola is not a new disease, the current outbreak stands apart because it is being caused by a rare strain of the virus, Bundibugyo.

Unlike previous outbreaks dominated by the Zaire strain of Ebola, the current epidemic, caused by the Bundibugyo virus, is a much less common species of the Ebola virus family.

The rarity of the strain has created unique scientific and emergency public health challenges, as there is currently no licensed vaccine designed to protect against Bundibugyo Ebola virus.

During outbreaks caused by the Zaire strain, vaccination became an important part of outbreak control. In the current epidemic, however, public health officials are being forced to rely heavily on rapid diagnosis, infection prevention, surveillance, and existing medical care.

Read more: Legionnaires' Disease Outbreak Grips NYC After At Least 14 Cases Reported Across 2 Neighborhoods

Bundibugyo Ebola Virus: Latest Developments

WHO Clears First Diagnostic Test

In a major scientific breakthrough, the World Health Organization (WHO) recently added the first molecular diagnostic test for the Bundibugyo Ebola virus to its Emergency Use Listing (EUL).

The test detects the virus's genetic material in blood samples, enabling laboratories to confirm infections more quickly and accurately.

First Treatment Trial Underway

WHO and its partners have launched the first clinical trial specifically evaluating treatments for Bundibugyo Ebola virus disease.

Researchers are testing the experimental monoclonal antibody MBP134, the antiviral drug remdesivir, and a combination of both to determine whether they can improve survival.

About Bundibugyo Ebola Virus

The Bundibugyo virus was first identified in Uganda in 2007 and has caused only a few outbreaks since then. As infections have been relatively uncommon compared to the Zaire strain, researchers have had limited opportunities to develop vaccines, treatments and diagnostic tests.

Due to this, healthcare workers have been compelled to rely primarily on rapid isolation of patients, intensive supportive care, contact tracing, and strict infection prevention measures to slow transmission.

Currently, Eastern DRC is the hotspot for the Bundibugyo Ebola outbreak, where conflict, population displacement, skepticism, and insecurity have made it difficult for health workers to reach affected locations.

Here, access to healthcare still remains uneven in many areas. Additionally, movement of people across districts and states in the country can accelerate the spread of infection significantly.

As scientists race to validate new diagnostics and evaluate experimental treatments, the Bundibugyo outbreak is becoming more than a public health emergency. It is also serving as a critical test of how quickly the global health community can develop and deploy new tools against an emerging infectious disease.